Management of DAAs Failure
If you have failure of plan A in treating a patient with chronic hepatitis C. What's your plan B
If you have failure of plan A in treating a patient with chronic hepatitis C. What's your plan B
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Abstract ID: 849<br />
Author: Ng T. et al.<br />
Analysis <strong>of</strong> HCV Variants in the MAGELLAN-1 Part 1 Study:<br />
• Number <strong>of</strong> patients: n=50.<br />
AASLD 2016<br />
ABT-493 and ABT-530 Glecaprevir/Pibrentasvir(G/P) Combination Therapy <strong>of</strong> Genotype 1-<br />
Infected Patients<br />
who Had Failed Prior Direct Acting Antiviral-Containing Regimens<br />
• These DAA-experienced patient cohorts had broad representation <strong>of</strong> baseline variants at key<br />
resistance-associated positions, including those at NS3 V36, Q80, R155, and D168, as well as<br />
NS5A M28, Q30, L31, and Y93.<br />
• Results: All patients with baseline variants at position Y93 in NS5A that confer high level <strong>of</strong><br />
resistance to currently approved NS5A inhibitors achieved SVR12<br />
• Conclusions: The combination <strong>of</strong> ABT-493 and ABT-530 demonstrated potent antiviral activity<br />
and a high barrier to resistance in non-cirrhotic HCV GT1-infected patients who had previously<br />
failed a DAA-containing regimen,
Change language